What the zero serious adverse events claim actually means

Since 2013, more than 19,000 patients worldwide have been treated with ChondroFiller® liquid, and across that entire dataset no serious adverse device effect (SADE) has been recorded. The overall complaint rate sits at approximately 0.06% — a figure that ranks among the lowest documented for any cartilage-repair intervention in the knee.

That number deserves a clear-eyed reading. It comes from Meidrix Biomedicals GmbH's Clinical Evaluation Report Version 09, published in April 2025 — a mandatory post-market clinical follow-up (PMCF) submission required under the EU Medical Device Regulation for CE Class III devices. CE Class III is the highest-risk regulatory tier and carries the most demanding evidence requirements; it is not, however, the same as a blinded randomised controlled trial. The dataset is manufacturer-compiled and should be understood as the most comprehensive real-world safety record available for the device, rather than as independent academic scrutiny.

For UK patients, one further point matters practically: ChondroFiller® holds CE Class III certification but is not FDA-approved and is not funded by the NHS — it is accessed privately under individual prescription.

Finally, the zero-SADE figure has a defined scope. It applies to patients with focal, contained Grade III or IV chondral defects and healthy surrounding cartilage borders. It does not extend to diffuse osteoarthritis or to patients treated outside those indications — a distinction that shapes every clinical conversation about suitability.

What post-market surveillance data captures — and what it misses

Within that surveillance framework, the adverse events that do appear are consistently localised. Fibrous tissue formation is the principal documented biological risk — and it arises specifically in overfilled defects; applications placed flush with the surrounding cartilage surface have been consistently free of it. Temporary joint crepitus has been noted in a small number of cases but resolves without intervention.

A distinct category of event also appears in the data: non-gelation, where the collagen hydrogel fails to polymerise correctly in situ. This occurs in approximately 0.01% of procedures and represents a technical procedural issue rather than a biological adverse reaction — no systemic consequence follows.

The safety record has a defined perimeter, set by the contraindications. Absolute exclusions include known hypersensitivity to murine (mouse-derived) Type I collagen, active joint infection, untreated bleeding disorders, active malignancy, and pregnancy. Advanced diffuse osteoarthritis — Kellgren-Lawrence Grade IV — is also an absolute contraindication; the zero serious adverse event rate applies only to patients with focal, contained Grade III or IV chondral defects and healthy surrounding borders. Patients outside those criteria sit outside the dataset.

Two evidence gaps remain worth stating plainly. No blinded randomised controlled trial has been completed for ChondroFiller® in the knee, which limits the strength of any causal inference from the surveillance figures. And published follow-up extends to three years at most, leaving long-term durability an open question. What the 19,000-case dataset captures well is broad real-world tolerability across a carefully selected, consistently defined patient group.

Imaging evidence: what MRI shows after ChondroFiller injection

MRI provides the clearest objective window on how the knee responds after a ChondroFiller® liquid injection. European studies use a validated cartilage-specific scoring system — MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue) — which grades defect fill, tissue integration, surface integrity, and subchondral bone status on a standardised 0–100 scale.

In published European cohorts, ChondroFiller® achieves MOCART scores of 81.6 to 84.3, indicating that more than 80% of the treated defect is filled with repair tissue that is integrating with surrounding native cartilage. That figure is not reached immediately: mean scores sit at approximately 65.3 at four weeks, rising to 81.6 at twelve months. The progression reflects how the acellular scaffold works — not by filling the defect in bulk on day one, but by gradually recruiting the patient's own progenitor cells to promote endogenous repair over time.

Beyond defect fill, post-injection MRI in knee patients shows reduction in bone marrow oedema and diminished periarticular effusion, alongside visible joint-space widening. These are biocompatibility markers — evidence that the joint is tolerating the scaffold rather than mounting an inflammatory response to it.

Mechanistic support for that cell-recruitment process comes from a 2025 ex vivo study using femoral condyle explants (n=61): DNA content within the ChondroFiller® scaffold increased 2.4-fold by day 14, confirming active, non-toxic cell migration into the acellular collagen matrix.

Functional outcomes: how patients' knees actually improve

The IKDC (International Knee Documentation Committee) scale runs from 0 to 100, and researchers have established that a change of at least 16.7 points represents the minimum a patient can reliably notice as a meaningful difference — the Minimal Clinically Important Difference (MCID). Across published ChondroFiller® knee studies, mean gains consistently approach double that threshold.

The most detailed follow-up data come from the Jerosch prospective PMCF study, which recorded a mean IKDC improvement of 32.4 points — sustained and slightly increased at three-year follow-up, with patients reaching a functional score of 80.1. That durability matters: cartilage repair studies frequently show early gains that erode over time, so maintained improvement at three years is a substantive finding.

Peer-reviewed trial evidence, though limited in scale, points in the same direction. The first randomised multicentre study (2016, n=23 knee patients) reported zero adverse events alongside statistically significant IKDC improvement at 3, 6, and 12 months. A separate cohort of 17 patients treated at the University Hospital Pleven, Bulgaria (mean age 31; JIMAB 2024), confirmed significant gains in both Lysholm scale and IKDC score at all three time points, with improvements plateauing between six and twelve months.

The pattern across these studies is coherent, but one limitation deserves plain statement: trial populations are small, predominantly European, and no large independent randomised controlled trial has been completed for ChondroFiller® in the knee. Consistency of direction across different study designs is reassuring; the certainty that only a powered RCT could provide remains, for now, absent.

How ChondroFiller's safety compares to surgical alternatives

Surgical cartilage repair options for the knee fall into two broad categories: microfracture, a single-stage marrow-stimulation procedure, and autologous chondrocyte implantation (ACI) or its matrix-assisted variant (MACI), a two-stage theatre-based operation. Compiled data place ChondroFiller® in a markedly different range from either.

Complication rates for ChondroFiller® sit at approximately 0%, against a 0–7% range for microfracture and up to 17% for ACI/MACI. The reoperation gap is wider still: 3–8% for ChondroFiller® compared with up to 41% for microfracture and up to 37% for ACI/MACI. Part of that difference reflects the procedural pathway itself. ChondroFiller® is administered as an ultrasound-guided outpatient injection under local anaesthesia — no theatre admission, no incisions, no surgical-wound recovery. Fewer procedural steps mean fewer opportunities for procedure-related complications.

The comparison with microfracture also carries a biological dimension. Microfracture typically stimulates fibrocartilage — a mechanically inferior repair tissue — rather than the hyaline-like cartilage that ChondroFiller® aims to support through acellular matrix-induced chondrogenesis. ACI and MACI may produce higher-quality repair tissue but require two separate operative episodes and extended rehabilitation.

Hyaluronic acid (HA) viscosupplementation is a separate category from all three. HA lubricates the joint surface and may offer temporary symptom relief; it does not fill a structural defect or provide a regenerative scaffold. For patients with a focal, contained cartilage lesion, the distinction matters — ChondroFiller® is targeting structural repair, not lubrication.

Who this evidence applies to — and what remains uncertain

The patients who make up the 19,000+ case dataset share a specific clinical profile: a focal, contained articular cartilage defect, graded III or IV, measuring up to 6 cm², with structurally sound surrounding cartilage borders and no diffuse joint degeneration. Those criteria define the indicated population — and the population from whom every safety and outcome figure in this article is drawn.

Patients outside that profile are outside the evidence base. Absolute contraindications — covering diffuse osteoarthritis, active infection, and several systemic factors discussed earlier in this article — mark the boundary beyond which the 0% serious adverse event rate does not apply. The headline figure is not a general claim about the device in all comers; it is a product of careful patient selection.

For UK patients, ChondroFiller® holds CE Class III certification under the EU Medical Device Regulation — the highest-risk regulatory tier — is not FDA-approved, and is not NHS-funded. Treatment is accessed privately following clinical assessment and imaging review. Lincolnshire Knee, part of the MSK Doctors group, accepts patients without a GP referral; consultation at the Sleaford or Grantham clinic will confirm whether defect characteristics and surrounding joint health meet the indication.

Two genuine uncertainties remain. Follow-up data currently extend to three years — a point at which functional gains are maintained — but longer-term durability is, as yet, uncharted. And all safety and efficacy data originate from manufacturer-sponsored post-market surveillance and small cohort studies: no blinded independent randomised controlled trial has been completed for the knee injection application. PMCF data at this scale represent a substantive form of real-world evidence; they are not a substitute for that trial, and the research gap remains open.

1. [1] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
2. [2] IMPLANTATION OF CHONDROFILLER LIQUID® AS A SCAFFOLD MATERIAL FOR THE TREATMENT OF CHONDRAL LESIONS OF THE KNEE JOINT. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
3. [3] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759